New insider activity at Cencora ( (COR) ) has taken place on December 19, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Senior Vice President and Chief Accounting Officer Lazarus Krikorian has recently cashed out a portion of his stake in Cencora, selling 4,031 shares of the company’s stock in a transaction valued at $1,383,560. This insider move highlights a significant monetization of equity by a top executive, drawing attention to trading activity within Cencora’s leadership ranks.
Recent Updates on COR stock
Over the last day, news on Cencora has focused on its reaffirmed long‑term growth outlook and strategic moves rather than notable price swings. The company reiterated its fiscal 2026 revenue growth target in the mid‑single digits, signaling confidence in continued expansion and execution. At the same time, it highlighted that, due to the pending acquisition of OneOncology, it is pausing share repurchases, which it expects will leave full‑year adjusted EPS toward the lower end of its guided range—this capital allocation shift and expected earnings impact are key factors behind recent analyst reassessments of the stock’s upside. Barclays initiated coverage with a positive view driven by a favorable stance on drug distributors within U.S. healthcare technology and distribution, contrasting with a more cautious stance on dental and healthcare IT, which supports optimism toward Cencora’s role in that value chain. Separately, the company disclosed heightened risk from unpredictable external shocks—such as pandemics, natural disasters, and geopolitical events—that could disrupt manufacturing, supply chains, and customer demand, a factor analysts must weigh against the otherwise strong growth and strategic acquisition story when updating their valuation models and price targets.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Neutral.
Cencora’s strong financial performance and positive earnings call sentiment are major strengths, driving the score. However, high leverage, potential overvaluation, and technical indicators suggesting bearish momentum are notable risks.
To see Spark’s full report on COR stock, click here.
More about Cencora
YTD Price Performance: 52.75%
Average Trading Volume: 1,451,021
Technical Sentiment Signal: Buy
Current Market Cap: $66.53B